New drug TB-500 aims to improve blood vessel health in heart disease patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 40-75 years, able to provide written informed consent. * Documented stable ASCVD (e.g., prior myocardial infarction \>6 months ago, prior coronary revascularization, stable angina with objective evidence of ischemia, or symptomatic peripheral artery disease). * On stable guideline-directed medical therapy (e.g., statin and antiplatelet therapy unless contraindicated) for at least 8 weeks before screening. * Resting systolic blood pressure \<160 mmHg and diastolic blood pressure \<100 mmHg (with or without therapy). * Able and willing to comply with study visits and procedures. Exclusion Criteria: * Acute coronary syndrome, stroke/transient ischemic attack, or coronary revascularization within 6 months before screening. * New York Heart Association (NYHA) class III-IV heart failure or left ventricular ejection fraction \<35%. * Clinically significant arrhythmia requiring recent hospitalization or unstable antiarrhythmic therapy. * Severe renal impairment (eGFR \<30 mL/min/1.73 m\^2) or end-stage renal disease. * Clinically significant hepatic impairment (e.g., Child-Pugh class B/C) or ALT/AST \>3x upper limit of normal at screening. * Active malignancy requiring systemic therapy (except adequately treated non-melanoma skin cancer) within the past 2 years. * Known autoimmune disease requiring systemic immunosuppression, or use of chronic systemic corticosteroids above physiologic replacement. * Pregnant or breastfeeding, or unwilling to use effective contraception during the study (if of childbearing potential). * Known hypersensitivity to peptide therapeutics or study formulation components. * Participation in another interventional clinical study or receipt of an investigational product within 30 days (or 5 half-lives, whichever is longer) prior to screening.